Literature DB >> 32594341

Prevalence of Immunological Defects in a Cohort of 97 Rubinstein-Taybi Syndrome Patients.

Francesco Saettini1, Richard Herriot2, Elisabetta Prada3, Mathilde Nizon4,5, Daniele Zama6, Antonio Marzollo7, Igor Romaniouk8, Vassilios Lougaris9, Manuela Cortesi9, Alessia Morreale9, Rika Kosaki10, Fabio Cardinale11, Silvia Ricci12, Elena Domínguez-Garrido13, Davide Montin14, Marie Vincent4,5, Donatella Milani3, Andrea Biondi15, Cristina Gervasini16, Raffaele Badolato8.   

Abstract

Although recurrent infections in Rubinstein-Taybi syndrome (RSTS) are common, and probably multifactorial, immunological abnormalities have not been extensively described with only isolated cases or small case series of immune deficiency and dysregulation having been reported. The objective of this study was to investigate primary immunodeficiency (PID) and immune dysregulation in an international cohort of patients with RSTS. All published cases of RSTS were identified. The corresponding authors and researchers involved in the diagnosis of inborn errors of immunity or genetic syndromes were contacted to obtain up-to-date clinical and immunological information. Ninety-seven RSTS patients were identified. For 45 patients, we retrieved data from the published reports while for 52 patients, a clinical update was provided. Recurrent or severe infections, autoimmune/autoinflammatory complications, and lymphoproliferation were observed in 72.1%, 12.3%, and 8.2% of patients. Syndromic immunodeficiency was diagnosed in 46.4% of individuals. Despite the broad heterogeneity of immunodeficiency disorders, antibody defects were observed in 11.3% of subjects. In particular, these patients presented hypogammaglobulinemia associated with low B cell counts and reduction of switched memory B cell numbers. Immunoglobulin replacement therapy, antibiotic prophylaxis, and immunosuppressive treatment were employed in 16.4%, 8.2%, and 9.8% of patients, respectively. Manifestations of immune dysfunctions, affecting mostly B cells, are more common than previously recognized in patients with RSTS. Full immunological assessment is warranted in these patients, who may require detailed investigation and specific supportive treatment. Graphical Abstract.

Entities:  

Keywords:  B cells; CREBBP; EP300; Rubinstein–Taybi syndrome; antibody deficiency; humoral defects; hypogammaglobulinemia; lymphoproliferation; syndromic immunodeficiency

Year:  2020        PMID: 32594341     DOI: 10.1007/s10875-020-00808-4

Source DB:  PubMed          Journal:  J Clin Immunol        ISSN: 0271-9142            Impact factor:   8.317


  4 in total

1.  Rubinstein-Taybi Syndrome in a Filipino Infant with a Novel CREBBP Gene Pathogenic Variant.

Authors:  Rhea Camille R Yumul; Mary Anne D Chiong
Journal:  Case Rep Genet       Date:  2022-05-21

2.  Genetic Diagnosis of Rubinstein-Taybi Syndrome With Multiplex Ligation-Dependent Probe Amplification (MLPA) and Whole-Exome Sequencing (WES): Case Series With a Novel CREBBP Variant.

Authors:  Yu-Rong Lee; Yu-Chen Lin; Yi-Han Chang; Hsin-Yu Huang; Yi-Kai Hong; Wilson Jr F Aala; Wei-Ting Tu; Meng-Che Tsai; Yen-Yin Chou; Chao-Kai Hsu
Journal:  Front Genet       Date:  2022-04-08       Impact factor: 4.772

3.  A Case of Common Variable Immunodeficiency with CREBP Gene Mutation without Rubinstein Taybi Syndrome Features.

Authors:  Ugur Musabak; Serdar Ceylaner; Tuba Erdogan; Ebru Sebnem Ayva
Journal:  Case Reports Immunol       Date:  2022-07-04

Review 4.  Rubinstein-Taybi Syndrome: A Model of Epigenetic Disorder.

Authors:  Julien Van Gils; Frederique Magdinier; Patricia Fergelot; Didier Lacombe
Journal:  Genes (Basel)       Date:  2021-06-24       Impact factor: 4.096

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.